Almirall S.A. stock (ES0157097017): focus on flexible dividend completion as trading stays active in Spain

Almirall S.A. shares in Spain remain in focus after the company completed a scrip-style flexible dividend with new shares and cash alternatives, while the stock continues to trade on BME under ISIN ES0157097017.

Almirall S.A. shares on the Spanish stock exchange remain in focus for domestic investors after the Barcelona-based dermatology specialist recently completed a flexible dividend program that offered shareholders a choice between new shares and cash, underlining the continued active listing of the stock in Spain.

The company, headquartered in Spain and listed on the Bolsa de Madrid under the ticker ALM and ISIN ES0157097017, executed a scrip-style dividend in which investors could opt for new shares or sell their rights back to the company for cash, according to a filing cited by Spanish financial media in late May 2026.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Almirall
• Sector/industry: Pharmaceuticals, dermatology-focused
• Headquarters/country: Barcelona, Spain
• Core markets: Europe and the United States
• Key revenue drivers: Prescription dermatology drugs and specialty pharmaceutical products
• Home exchange/listing venue: Bolsa de Madrid (ALM)
• Trading currency: EUR

Almirall S.A.: core business model

Almirall operates as a Spain-based specialty pharmaceuticals group centered on medical dermatology, with sales largely generated by prescription treatments for chronic skin conditions across Europe and select international markets.

Almirall S.A. in peer comparison

Within the European dermatology and specialty pharma universe, Almirall is often viewed alongside peers such as Denmark-based Leo Pharma in prescription dermatology and German-listed Dermapharm, which also focuses on branded specialty medicines and consumer health products in Europe.

Compared with larger diversified pharmaceutical groups active in dermatology, such as France-based Sanofi and Denmark's Novo Nordisk, Almirall remains more concentrated on skin-related diseases, positioning the company as a focused mid-cap player in Spain's healthcare sector rather than a broad-based multinational.

Conclusion

The completion of Almirall S.A.'s flexible dividend program underscores that the Barcelona-based dermatology specialist remains actively traded on the Spanish market, with shareholders recently having the option to receive new shares or cash. In comparison with European dermatology and specialty pharma peers, the company continues to represent a mid-cap, skin-focused profile within Spain's healthcare sector, and investors are likely to keep tracking any further corporate actions, earnings updates, or regulatory milestones that could influence market sentiment toward the stock.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.